Safety and Efficacy of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroid in Moderate-to-Severe Atopic Dermatitis.
Clinical trial NCT04250337 · COMPLETED
Trial details
- NCT number
- NCT04250337
- Sponsor
- Eli Lilly and Company
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2020-02-03
- Primary completion
- 2021-08-11
- Enrollment
- 228
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.